Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.

The Prostate·2026
Same author

Dose response OECD 216 studies for agrochemicals.

Integrated environmental assessment and management·2026
Same author

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

The Journal of clinical investigation·2026
Same author

Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304).

European urology oncology·2026
Same author

Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes.

European urology open science·2026
Same journal

Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Long-term Oncological and Functional Outcomes from a Large Single-center Cohort.

European urology oncology·2026
Same journal

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

European urology oncology·2026
Same journal

Overall Survival Benefit from Metformin in High-volume Metastatic Hormone-sensitive Prostate Cancer in STAMPEDE Signals an Opportunity for Metabolically-targeted Therapies in Prostate Cancer.

European urology oncology·2026
Same journal

Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.

European urology oncology·2026
Same journal

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.

European urology oncology·2026
Same journal

PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients?

European urology oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

611

Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.

Mark C Markowski1, Yi Ren2, Meghan Tierney2

  • 1John Hopkins University, Baltimore, MD, USA.

European Urology Oncology
|December 12, 2024
PubMed
Summary
This summary is machine-generated.

A new multimodal artificial intelligence (MMAI) biomarker shows prognostic ability in metastatic hormone-sensitive prostate cancer (mHSPC). This AI tool can identify patients at higher risk for worse outcomes, aiding treatment decisions.

Keywords:
Artificial intelligenceBiomarkerDigital pathologyPrognosisProstate cancer

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.7K

Related Experiment Videos

Last Updated: Jun 5, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

611
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.7K

Area of Science:

  • Oncology
  • Artificial Intelligence in Medicine
  • Biomarker Discovery

Background:

  • Personalized medicine for metastatic hormone-sensitive prostate cancer (mHSPC) requires prognostic and predictive biomarkers.
  • Treatment options and clinical subgroups in mHSPC necessitate tailored therapeutic strategies.

Purpose of the Study:

  • To evaluate a multimodal artificial intelligence (MMAI) biomarker for its prognostic capability in mHSPC.
  • To assess the association of MMAI scores with overall survival (OS), clinical progression (CP), and castration-resistant prostate cancer (CRPC).

Main Methods:

  • Utilized data from the phase 3 CHAARTED trial, including digital histopathology images and clinical variables from 456 patients with mHSPC.
  • Generated MMAI scores and assessed their association with OS, CP, and CRPC using Cox proportional-hazards and Fine-Gray models.

Main Results:

  • The MMAI biomarker demonstrated significant prognostic ability for OS, CP, and CRPC.
  • Patients classified as MMAI-high risk had significantly worse 5-year OS (39%) compared to MMAI-intermediate (58%) and MMAI-low (83%) groups.
  • The MMAI score remained prognostic across different clinical subgroups and after adjusting for treatment and clinical variables.

Conclusions:

  • The MMAI biomarker is a valuable prognostic tool for patients with mHSPC, irrespective of clinical subgroup or treatment.
  • Further research into MMAI biomarkers is warranted for advanced prostate cancer management.
  • AI-driven tools show potential in enhancing clinical decision-making for prostate cancer patients.